Search results
Results from the WOW.Com Content Network
Nintedanib is used for the treatment of idiopathic pulmonary fibrosis. [9] It has been shown to slow down decrease in forced vital capacity, [10] [11] and it also improves people's quality of life. [12] Nintedanib does not improve survival in people with IPF. [13]
Patients with idiopathic pulmonary fibrosis were randomly assigned to treatment with oral pirfenidone or placebo for a minimum of 72 weeks. [47] In study 004, pirfenidone reduced decline in forced vital capacity. Mean change in FVC at week 72 was –8.0% in the pirfenidone 2403 mg/day group and –12.4% in the placebo group, a difference of 4.4%.
[3] [12] A recent study from the US estimated the incidence of IPF to be between 6.8 and 16.3 per 100,000 persons. In the 27 European Union countries, a range of sources estimate an incidence of 4.6–7.4 people per 100,000 of the population, [ 73 ] [ 74 ] suggesting that approximately 30,000–35,000 new patients will be diagnosed with IPF ...
[1] [3] [6] But in most cases the cause is unknown (idiopathic pulmonary fibrosis). [1] [3] Diagnosis may be based on symptoms, medical imaging, lung biopsy, and lung function tests. [1] No cure exists and treatment options are limited. [1] Treatment is directed toward improving symptoms and may include oxygen therapy and pulmonary rehabilitation.
1.3 Clinical studies The clinical efficacy and safety of nintedanib in IPF has been established in 1,231 patients with IPF in one Phase II clinical trial (TOMORROW) and two replicate Phase III clinical trials, INPULSIS®-1 and -2.[18][21] These were double blind, randomised and placebo-controlled trialscomparing treatment with nintedanib 150 mg ...
The PR64 specimen sold via Heritage Auctions in 2014 for nearly $3.3 million, while a PR63-graded example sold for almost $3.2 million in 2013 via the same auction house.
Ziritaxestat is a small-molecule, selective autotaxin inhibitor that was investigated as a potential treatment for idiopathic pulmonary fibrosis (IPF). [1] Initially showing promise in early-phase studies, ziritaxestat underwent evaluation in two large-scale phase 3 clinical trials, ISABELA 1 and ISABELA 2.
Admilparant is an investigational new drug being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist. [1] [2] As of 2024, admilparant is in Phase III clinical trials for both IPF and PPF. [2] [3]